BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $46.25.

BIOA has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Piper Sandler initiated coverage on BioAge Labs in a report on Tuesday, January 27th. They set an “overweight” rating on the stock. Citigroup increased their price objective on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Morgan Stanley set a $23.00 price objective on BioAge Labs in a report on Wednesday, February 4th. Finally, Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a report on Saturday.

BioAge Labs Price Performance

Shares of BIOA stock opened at $17.99 on Monday. BioAge Labs has a fifty-two week low of $3.67 and a fifty-two week high of $24.00. The stock’s 50-day moving average is $18.55 and its two-hundred day moving average is $15.38. The firm has a market cap of $798.40 million, a P/E ratio of -7.50 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The business had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 31.95% and a negative net margin of 871.75%. As a group, research analysts expect that BioAge Labs will post -2.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new stake in BioAge Labs in the 3rd quarter valued at approximately $181,000. R Squared Ltd acquired a new stake in BioAge Labs in the 3rd quarter valued at approximately $154,000. Barclays PLC grew its holdings in BioAge Labs by 9.3% in the 4th quarter. Barclays PLC now owns 37,780 shares of the company’s stock valued at $500,000 after buying an additional 3,222 shares during the last quarter. Quadrature Capital Ltd grew its holdings in BioAge Labs by 56.2% in the 4th quarter. Quadrature Capital Ltd now owns 16,769 shares of the company’s stock valued at $222,000 after buying an additional 6,035 shares during the last quarter. Finally, Militia Capital Partners LP acquired a new stake in BioAge Labs in the 2nd quarter valued at approximately $166,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.